Factors associated with high 24-month persistence with denosumab: results of a real-world, noninterventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium

A. Fahrleitner-Pammer¹ · N. Papaioannou² · E. Gielen³ · M. Feudjo Tepie⁴ · C. Toffis⁵ · I. Frieling⁶ · P. Geusens⁷ · P. Makras⁸ · E. Boschitsch⁹ · J. Callens¹⁰ · A. D. Anastasilakis¹¹ · C. Niedhart¹² · H. Resch¹³ · L. Kalouche-Khalil¹⁴ · P. Hadji¹⁵

¹Department of Endocrinology and Metabolism, Medical University Graz, Graz, Austria

²University of Athens, Medical School, Laboratory for the Research of Musculoskeletal System, KAT Hospital, Athens, Greece

³Department of Geriatrics and Center for Metabolic Bone Diseases, UZ Leuven, Leuven, Belgium

⁴Amgen Ltd, Uxbridge, UK

⁵Amgen Ltd, Cambridge, UK

⁶Osteoporosis Center, Hamburg, Germany

⁷Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, Netherlands and University Hasselt, Diepenbeek, Belgium

⁸Department of Endocrinology and Diabetes, 251 Hellenic Airforce and VA General Hospital, Athens, Greece

⁹Ambulatorium KLIMAX, Menopause and Osteoporosis Clinic, Vienna, Austria

¹⁰Department of Orthopedics, Rheumatology and Physical Medicine and Rehabilitation, AZ Zeno Knokke, Belgium

¹¹Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece

¹²Osteoporosis Center, Heinsberg, Germany

¹³Medical Department II, St Vincent Hospital, Academic Teaching Hospital of the Medical University of Vienna, Vienna, Austria and Medical Faculty, Sigmund Freud University, Vienna, Austria

¹⁴Amgen (Europe) GmbH, Zug, Switzerland

1

¹⁵Department of Obstetrics and Gynecology, Krankenhaus Nordwest, Frankfurt, Germany

Corresponding author:

P. Hadji

Department of Obstetrics and Gynecology, Krankenhaus Nordwest, Frankfurt, Germany

Journal: Osteoporosis International

Electronic Supplementary Material

Online Resource 1 Covariates entered into the multivariable analysis model and statistically significant associations with 24-month persistence

Covariate		Country			
	Germany	Austria	Greece	Belgium	
Age			<u>p < 0.0001</u>		
Currently smoking			<u><i>p</i> = 0.0246</u>		
Formerly smoking			<i>p</i> = 0.1776		
Modified Wolfe comorbidity index	<u><i>p</i> = 0.0481</u>	<i>p</i> = 0.0541			
Any chronic medical condition	<u><i>p</i> = 0.0065</u>				
Number of concomitant medications taken at baseline			<i>p</i> = 0.1596		
≥1 fall in the 12 months prior to enrollment	<u><i>p</i> = 0.0381</u>		<i>P</i> = 0.2133	<u>p = 0.0269</u>	
≥2 historical fractures		<i>p</i> = 0.0525			
History of hip fracture			<i>p</i> = 0.0838		
≥1 occurrence of immobility in the 12 months prior to enrollment		<u><i>p</i> = 0.0193</u>			
Previous PMO therapy in the 12 months before enrollment			<i>p</i> = 0.0751		
History of discontinuation of osteoporosis therapy (not calcium or vitamin D)			<i>p</i> = 0.1940		
Reason for prescribing: failed other available osteoporosis therapy	<i>p</i> = 0.1259		<u><i>p</i></u> = 0.0330		
Reason for prescribing: intolerant to other osteoporosis therapy			<i>p</i> = 0.1063		
Reason for prescribing: multiple risk factors for fracture	<i>p</i> = 0.0999	<i>p</i> = 0.1633			
Reminder service available		<u><i>p</i> = 0.0179</u>	<u>p = 0.0058</u>		
Academic center	<u><i>p</i> = 0.0105</u>	<u>p = 0.0038</u>		<u><i>p</i> = 0.0015</u>	
Employment status			<i>p</i> = 0.1495		
Center type	<i>p</i> = 0.0681				
Proximity to clinic (minutes)				<i>p</i> = 0.1266	
Region	<i>p</i> = 0.1721				
Cause of menopause		<i>p</i> = 0.1119			
Physician sex		<i>p</i> = 0.1320	<u><i>p</i> = 0.0491</u>		
Physician specialty	<i>p</i> = 0.0991	<u><i>p</i> < 0.0001</u>		<u>p = 0.0492</u>	
Physician years of practice		<u><i>p</i> = 0.0161</u>	<i>p</i> = 0.0580		
Prior calcium and/or vitamin D supplements		<i>p</i> = 0.1047	<i>p</i> = 0.0610		


P values show the statistical significance of the covariate in the country-specific model, with p values <0.05 considered to be significant (shown underlined). Covariates in bold text were


considered to be clinically relevant

PMO postmenopausal osteoporosis

<mark>Key shown below</mark>

Covariate not eligible for inclusion in the country-specific model	Covariate significantly associated with 24-month persistence
Covariate not significantly associated with 24-month persistence	





Data are shown as mean percentages ± 95 % Cls

The MCR was calculated as the percentage of time that a patient was covered by denosumab, as assessed from prescription records, and was based on the assumption that each injection of denosumab provides 6 months of medication coverage *Cl* confidence interval, *MCR* medication coverage ratio

	Germany	Austria	Greece	Belgium
	(<i>N</i> = 579)	(<i>N</i> = 300)	(<i>N</i> = 299)	(<i>N</i> = 301)
Persistence, %				
6 months + 4 weeks	65.3 (61.3–69.2)	69.3 (63.8–74.5)	72.6 (67.1–77.6)	76.4 (71.2–81.1)
6 months + 6 weeks	72.2 (68.4–75.8)	78.0 (72.9–82.6)	79.3 (74.2–83.7)	81.7 (76.9–85.9)
6 months + 12 weeks	77.4 (73.7–80.7)	82.0 (77.2–86.2)	86.6 (82.2–90.3)	87.7 (83.5–91.2)
Adherence, %				
6 months ± 6 weeks	71.2 (67.3–74.8)	77.0 (71.8–81.6)	78.6 (73.5–83.1)	79.7 (74.7–84.1)
6 months ± 8 weeks	74.8 (71.0–78.3)	79.7 (74.7–84.1)	81.9 (77.1–86.1)	85.0 (80.5–88.9)
6 months ± 12 weeks	77.2 (73.6–80.6)	82.0 (77.2–86.2)	86.6 (82.2–90.3)	87.0 (82.7–90.6)

Online Resource 3 Sensitivity analysis of persistence and adherence with denosumab at 24 months

Data are shown as percentages (95 % confidence intervals)